Kidney Transplant Rejection

Kidney transplant rejection is an immunologic process in which the recipient's immune system recognizes the allograft as foreign and mounts a destructive response, classified by timing and mechanism into hyperacute, acute T-cell-mediated, acute antibody-mediated, and chronic rejection. Also called: allograft rejection, renal allograft rejection, transplant rejection, graft rejection. The ICD-10 code T86.100 is used for kidney transplant rejection in administrative data, with a positive predictive value of 83.8% for biopsy-confirmed rejection, though its sensitivity is only 72.9% ^[3]B2b.

Classification by Timing and Mechanism

Rejection types are defined by the time of onset relative to transplantation and the predominant effector mechanism.

Subclinical rejection (SCR) is a histologic entity defined by evidence of rejection on protocol biopsy in the absence of graft dysfunction ^[1]D5. Its detection and management remain debated, as the natural history of untreated SCR is incompletely understood ^[1]D5.

Clinical Significance

Rejection is the leading cause of graft loss after the first year post-transplant. Antibody-mediated rejection in particular accounts for a large proportion of long-term allograft losses and has proven resistant to standard immunosuppression, creating an urgent need for effective therapies ^[1]D5. The histologic features of acute TCMR closely mimic immune-checkpoint inhibitor-associated nephritis, which can be managed using the same treatment algorithms ^[2]C4.

The next section details the pathophysiology and mechanism of each rejection type, exploring the cellular and humoral pathways that drive these distinct clinical entities.

Pearl: The ICD-10 code T86.100 has a PPV of 83.8% for biopsy-confirmed rejection, making it a useful tool for administrative research despite moderate sensitivity.

From this classification, the distinct immunopathologic pathways that drive each rejection type become apparent. Hyperacute rejection, now rare, results from preformed recipient antibodies (anti-HLA or anti-ABO) that bind graft endothelium within minutes of reperfusion, triggering massive complement activation, neutrophil infiltration, and widespread microvascular thrombosis ^[11]B3b. The graft is irretrievably lost unless removed.

Acute T-Cell Mediated Rejection

Acute TCMR is driven by recipient T cells that recognize donor alloantigens through direct (donor dendritic cells) or indirect (recipient antigen-presenting cells) pathways. CD4+ helper T cells provide costimulation and cytokine help, while CD8+ cytotoxic T lymphocytes (CTLs) mediate epithelial injury. CTLs use perforin and granzyme B to induce tubular epithelial cell apoptosis, but alternative contact-independent mechanisms, delayed-type hypersensitivity (DTH) mediated by cytokines such as IFN-γ and TNF-α, also contribute, as tubulitis and cadherin loss occur even in the absence of perforin, granzymes A/B, or CD103 ^[16]D5. The chemokine IL-16, produced by tubular epithelial cells, recruits CD4+ T cells into the interstitium, amplifying the inflammatory cascade ^[9]D5. Myeloid-derived suppressor cells (MDSCs) expressing S100A8 and S100A9 can counter-regulate this response by inhibiting dendritic cell maturation and T cell activity via reactive oxygen species, linking intragraft S100A8/A9 expression to improved outcomes in acute rejection ^[8]B2b.

Acute Antibody-Mediated Rejection

ABMR is initiated by donor-specific antibodies (DSA), most commonly against HLA class I or II, but also against non-HLA targets such as angiotensin II type 1 receptor (AT1R) and other glomerular endothelial cell antigens ^{[11]B3b[19]C4}. DSA binding to graft microvascular endothelium activates the classical complement pathway, depositing C4d in peritubular capillaries and glomeruli. Complement activation recruits neutrophils and macrophages, while Fc-receptor engagement on NK cells triggers antibody-dependent cellular cytotoxicity (ADCC). NK cells, which express CD38, are key effectors in microvascular inflammation ^[24]D5. The proinflammatory cytokine IL-6 amplifies this loop by promoting B cell differentiation into plasma cells, enhancing DSA production, and driving T follicular helper cell responses ^[7]A1b[20]D5. Three ABMR subphenotypes emerge: early pgABMR (peritubular capillaritis/glomerulitis, often mixed with TCMR), late cgABMR (glomerular double contours), and the most common combined pgcgABMR ^[15]B2b. Notably, up to 46% of ABMR cases lack detectable DSA by conventional assays, yet show identical molecular and prognostic features when all DSA are considered positive, suggesting that current DSA testing underestimates true ABMR burden ^[14]C4.

Chronic Rejection and Transplant Glomerulopathy

Chronic active ABMR (CAAMR) evolves from persistent DSA-mediated microvascular injury, leading to progressive glomerular basement membrane duplication (cg lesions), peritubular capillary basement membrane multilayering, and interstitial fibrosis/tubular atrophy (IFTA). Proteogenomic analysis of IFTA biopsies reveals extensive activation of the alternative complement pathway (previously underappreciated), along with immune response, inflammatory cell activation, and apoptosis pathways ^[10]C4. The actin cytoskeleton and acute-phase response networks are also dysregulated, reflecting ongoing tissue remodeling and injury ^[10]C4. CAAMR remains the leading cause of late graft loss, and no effective therapy has been established ^[25]D5. Regulatory mechanisms such as IL-10 can suppress alloimmunity, in a rat model, IL-10 gene therapy reduced proinflammatory cytokines and prolonged graft survival from 22% to 90% ^[17]D5, but such pathways are often overwhelmed in chronic rejection.

Pearl: The distinction between TCMR and ABMR is not absolute; mixed rejection occurs in ~20% of biopsies, and DSA-negative ABMR is common, always consider non-HLA antibodies (e.g., AT1R) and molecular phenotyping when DSA is absent but histology suggests microvascular injury ^{[11]B3b[14]C4[15]B2b}.

The pathophysiology outlined above translates into a clinically significant burden: acute rejection rates vary widely, but late or vascular rejection episodes disproportionately drive graft loss. Precisely quantifying the incidence and risk factors directs the pretest probability for workup and guides preventive strategies.

Incidence and Prevalence

Antibody-mediated rejection (AMR) is the leading cause of graft failure. The reported incidence of acute AMR ranges from 1.1% to 21.5% across cohorts, with most studies reporting 3% to 12% within the first year post-transplant ^[35]B2a. Chronic AMR accumulates over time, with an incidence of 7.5% to 20.1% up to 10 years ^[35]B2a. For acute cellular rejection, rates have fallen in the modern era but remain substantial: in the ANZDATA Registry (1997-2004), 1961 rejection episodes occurred among 4325 grafts ^[40]B2b, and in a phase 2 trial of TOL101, 13.9% of recipients experienced biopsy-confirmed acute cellular rejection ^[27]C4. Conversion from calcineurin inhibitor (CNI) to belatacept-based maintenance yielded a numerically higher BPAR rate of 8% versus 4% with CNI continuation ^[26]A1b.

Temporal Trends

Crude rejection rates fell by one-third between 1997 and 2004 in Australia and New Zealand ^[40]B2b. Despite this decline, rates of graft survival remained constant, suggesting that the reduced incidence of early acute rejection has not yet translated into improved long-term graft outcomes ^[40]B2b. This paradox highlights the persisting impact of late and antibody-mediated rejection.

Risk Factors

Risk factors for rejection and graft loss span recipient, donor, and transplant-related domains. The table below summarizes the most impactful factors with available effect estimates.

Special Considerations

Nonadherence is a major modifiable risk factor, particularly for early, T-cell-mediated rejection. In the Utah Population Database, a familial component to rejection-free survival suggests shared genetic factors ^[36]B3b. Psoriasis, a systemic inflammatory disorder, independently increases the risk of graft failure via immune-mediated pathways ^[12]B2b. Donor-derived cell-free DNA (dd-cfDNA) has emerged as a biomarker for rejection, with AUC of 0.79-0.80 for discriminating rejection, and when combined with clinical parameters, AUC improves to 0.87 ^[29]B2b. DSA-negative antibody-mediated rejection is increasingly recognized; alternative diagnostic strategies (e.g., calling all DSA as positive) can identify 46% more cases with equivalent graft loss risk ^[14]C4.

Pearl: The single most actionable risk factor for rejection is medication nonadherence, up to 68% of US transplant programs report graft losses attributable to cost-related nonadherence, making adherence support a high-yield intervention ^[33]C4.

From the risk factors discussed above, the transition to clinical disease is often silent. After the first year, many patients harbour subclinical rejection, defined by histologic injury without concurrent graft dysfunction, that is detectable only through surveillance biopsy. This silent phase may be the most common presentation of both T-cell mediated (TCMR) and antibody-mediated rejection (ABMR) in the modern era ^[46]D5.

Symptomatic Acute Rejection

When overt, acute rejection typically presents within the first weeks to months post-transplant. The classic triad of fever, graft tenderness, and oliguria is now rare with modern immunosuppression; more frequently, the patient has an asymptomatic rise in serum creatinine. Hyperacute rejection, occurring intraoperatively or within minutes to hours, manifests as a mottled, cyanotic graft with immediate anuria, a surgical emergency requiring prompt graft removal. For acute TCMR and ABMR, the onset is subacute: a rise in creatinine of ≥0.3 mg/dL or ≥25% from baseline over days, often accompanied by new-onset hypertension , edema, or a flu-like syndrome. Proteinuria may be present, especially in ABMR.

Chronic Rejection and Subphenotypes

Chronic ABMR evolves insidiously over years. The key clinical clue is a slow, progressive decline in eGFR with worsening proteinuria. Three subphenotypes have been described: early pgABMR (microcirculation inflammation dominant, median onset <2 years), late cgABMR (transplant glomerulopathy with double contours, median onset 9 years), and a combined pgcgABMR phenotype that dominates at all time intervals ^[15]B2b. The late ABMR phenotype is often diagnosed in the BORTEJECT trial cohort at a median 5.0 years post-transplant, confirming that DSA-positive ABMR can be clinically silent before functional decline accelerates ^[6]A1b.

Red Flags

• Rapid rise in creatinine over 24 hours - suspect hyperacute or accelerated acute rejection.
• Anuria with graft tenderness - urgent biopsy and Doppler ultrasound needed.
• Fever without infection - may indicate acute rejection, especially in the early post-transplant period.
• New or worsening proteinuria - hallmark of chronic ABMR.

Atypical Presentations

Rejection may be unmasked by immune checkpoint inhibitors (ICIs). In a case report of a kidney transplant recipient treated with nivolumab for melanoma , donor-derived cell-free DNA (dd-cfDNA) rose to 23% within 12 days of the first dose, preceding clinical deterioration ^[55]C4. Such presentations are increasingly recognized in the ICI era and require a high index of suspicion.

Additionally, the gut microbiome shows distinct signatures: patients with acute rejection have reduced bacterial richness, increased Escherichia-Shigella, and decreased fecal propionate and lactate concentrations compared with stable recipients ^[54]B2b. While not yet a clinical tool, these metabolic shifts may become part of future risk stratification.

Pearl: The most common presentation of kidney transplant rejection is no presentation at all, subclinical rejection on surveillance biopsy is the rule, not the exception. A rise in creatinine of ≥25% from baseline, even without symptoms, mandates urgent investigation.

From the clinical presentation of graft dysfunction, the diagnostic workup proceeds along a structured pathway to confirm or exclude rejection and to classify its type and severity. The gold standard for diagnosis is a percutaneous renal allograft biopsy interpreted according to the Banff classification ^[44]D5. However, noninvasive biomarkers are increasingly used to stratify risk and reduce the need for surveillance biopsies.

Laboratory Studies

Serum creatinine and eGFR trajectory remain the cornerstone of monitoring, but they lack specificity: a rise in creatinine can reflect rejection, calcineurin inhibitor toxicity, infection, or recurrent disease. Donor-specific antibodies (DSA) are measured using single-antigen bead assays; their presence supports antibody-mediated rejection (ABMR), but absence does not exclude it. In the Trifecta-Kidney study, calling all DSA as positive identified 46% more ABMR cases with no measurable conventional DSA, and these cases had the same risk for graft loss as DSA-positive ABMR ^[14]C4. Proteinuria (urine protein-to-creatinine ratio) and urinalysis with sediment microscopy may show hematuria or pyuria but are nonspecific.

Noninvasive Biomarkers

Several blood- and urine-based biomarkers have been validated for rejection detection (Table 1). Donor-derived cell-free DNA (dd-cfDNA) is the most extensively studied: for ABMR, pooled sensitivity is 0.81 (95% CI 0.72-0.88), specificity 0.80 (95% CI 0.73-0.86), and AUROC 0.87 ^[53]A1a. A dd-cfDNA threshold >0.5% is independently associated with ABMR (OR 21.9, 95% CI 3.74-180) and with Banff ≥1A T-cell mediated rejection (TCMR) (OR 5.37) ^[62]B3b. Urinary chemokines CXCL9 and CXCL10, normalized to creatinine, integrated with clinical markers (eGFR, DSA, polyoma viremia) yield an AUROC of 81.3% (95% CI 77.6-85.0) for acute rejection; the model could avoid 59 protocol biopsies per 100 patients when predicted risk is below 10% ^[42]B2b. Peripheral blood gene expression signatures such as Tutivia (AUC 0.69, 95%) outperform serum creatinine alone (AUC 0.51) for predicting early acute rejection, with a negative predictive value of 0.79 ^[52]B2b. Circulating cell-free nucleosomes (total H3) show an AUC of 0.73 for acute rejection with a negative predictive value of 92.9% ^[32]B2b.

Biopsy and Histology

Biopsy is required for definitive diagnosis. The Banff classification scores key lesions: tubulitis (t), intimal arteritis (v), glomerulitis (g), peritubular capillaritis (ptc), C4d deposition in peritubular capillaries, and transplant glomerulopathy (cg) ^[44]D5. Immunohistochemistry for C4d is a marker of complement activation in ABMR, but C4d-negative ABMR is recognized. Molecular assessment using gene expression panels (e.g., NanoString Banff Human Organ Transplant panel) improves classification accuracy: a multiclass model achieved 80% overall accuracy in validation, with ≥75% positive predictive value for each class except mixed rejection ^[48]B3b. A simpler 17-gene RT-MLPA assay from formalin-fixed paraffin-embedded tissue classified rejection with an overall accuracy of 0.83 ^[49]C4. Proteomic profiling of biopsies has identified candidate markers such as GNB4 and PDK1 that may help distinguish borderline from acute TCMR ^[63]B3b.

Diagnostic Algorithm

Step 1: Clinical suspicion - rising creatinine, new or increasing proteinuria, de novo DSA, or symptoms (fever, graft tenderness). Step 2: Noninvasive risk stratification - measure dd-cfDNA and/or urinary CXCL9/CXCL10. A dd-cfDNA <0.5% makes ABMR unlikely (high NPV). Step 3: Biopsy - perform for-cause biopsy if biomarkers are positive or if clinical suspicion remains high despite negative biomarkers. Step 4: Histologic and molecular classification - apply Banff 2022 criteria, supplemented by molecular testing (MMDx, NanoString, or RT-MLPA) when available. Step 5: Integration - combine histology, DSA status, and biomarker results to classify rejection type (TCMR, ABMR, mixed) and guide treatment.

Table 1. Noninvasive Biomarkers for Kidney Transplant Rejection

Pearl: A negative dd-cfDNA (<0.5%) has a high negative predictive value for ABMR, making it a useful rule-out test, but biopsy remains essential for definitive diagnosis and classification because DSA-negative ABMR is common and noninvasive biomarkers cannot yet replace histology ^{[14]C4[53]A1a}.

Once the diagnosis of allograft rejection is established, the next step is to stratify its severity and the patient's immunological risk to guide therapy. The KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients provides a framework that integrates histologic grading (Banff classification) with clinical risk factors to drive treatment decisions.

Risk Stratification Based on Immunological Profile

Immunological risk assessment begins before transplantation but must be updated at the time of rejection. The European Society for Organ Transplantation (ESOT) working group, in collaboration with the European Medicines Agency, identified several key determinants ^[64]D5:

• HLA matching: Transplantations between HLA-identical donors and recipients carry significantly lower immunological risk than those from HLA-mismatched donors ^[64]D5.
• Donor type: For the same allogeneic molecular HLA mismatch load, kidney grafts from living donors carry significantly lower immunological risk because they are better preserved and therefore less immunogenic than grafts from deceased donors ^[64]D5.
• Donor-specific antibodies (DSA): Single-antigen bead testing is the gold standard to establish the repertoire of serological sensitization and is used to define the presence of a recipient's circulating HLA-DSA ^[64]D5.
• Molecular HLA mismatch analysis: Although no consensus algorithm or cut-off exists, molecular mismatch analysis may help further improve organ allocation compatibility and stratify immunological risk for primary alloimmune activation ^[64]D5.
• Other immune assays: Assays measuring anti-donor cellular memory (T/B cell ELISpot) and non-HLA-DSA require further clinical validation before routine use ^[64]D5.

For low-to-moderate immunological risk adult recipients, an everolimus-based regimen with reduced-exposure calcineurin inhibitor and low-dose steroids is a suitable prophylaxis option, with individualized management ^[66]D5. Induction with either basiliximab or rabbit anti-thymocyte globulin is effective when initiating such a regimen ^[66]D5.

KDIGO Classification of Rejection Severity

KDIGO endorses the Banff working scheme for histopathological diagnosis and grading of rejection. The Banff classification has undergone periodic revisions, incorporating immunological and clinical insights, epidemiological studies, and molecular diagnostics ^[65]D5. For T-cell mediated rejection (TCMR), grades include borderline changes (suspicious for acute TCMR), IA, IB, IIA, IIB, and III. For antibody-mediated rejection (AMR), grading is based on microvascular inflammation, transplant glomerulopathy, and C4d deposition. This histologic severity directly drives the KDIGO treatment algorithm.

KDIGO Treatment Recommendations by Stage

The KDIGO guideline for acute rejection treatment recommends use of corticosteroids as first-line therapy for TCMR ^[65]D5. A European survey of 129 transplant professionals found that the majority of centres treat borderline changes and TCMR grade IA-B and IIA-B with corticosteroids as first-line treatment in both indication and protocol biopsies ^[65]D5. Thymoglobulin (rabbit anti-thymocyte globulin) is used as second-line treatment for TCMR grade IA-B (80% of centres) and TCMR grade IIA-B (85% of centres) ^[65]D5. Treatment success is most often evaluated within one month of therapy ^[65]D5. This tiered approach, corticosteroids first, lymphocyte-depleting agents second for more severe or steroid-resistant cases, reflects the KDIGO staging paradigm where histologic grade determines treatment intensity.

Pearl: The Banff histologic grade of rejection, especially the distinction between borderline/IA and IIB/III, is the primary determinant of whether to escalate to lymphocyte-depleting therapy, and the immunological risk profile (HLA mismatch, DSA status, donor type) should be reassessed at the time of rejection to guide maintenance immunosuppression adjustment.

With KDIGO risk stratification applied, the next step is immediate intervention for an acute rejection episode, guided by its immunopathologic type. The management pathway is time-critical and protocolized, paralleling the approach to nephrologic emergencies such as severe hyperkalemia or pulmonary edema, where the AEIOU criteria (Acidosis, Electrolytes, Intoxication, Overload, Uremia) trigger emergent dialysis. For transplant rejection, the choice of first-line therapy hinges on the Banff classification and the presence of donor-specific antibodies (DSA).

Step 1: Initial Assessment and Severity Classification

Immediately after biopsy confirmation, classify the rejection as hyperacute, acute T-cell mediated (TCMR), or acute antibody-mediated (ABMR). Hyperacute rejection presents within minutes to hours and requires urgent graft removal. Acute TCMR (Banff borderline or grade I-III) and acute ABMR are managed medically. The presence of DSA and C4d staining on biopsy distinguish ABMR. Concurrent assessment for severe complications, fluid overload, metabolic acidosis, or symptomatic uremia, determines whether hemodialysis is needed before or alongside rejection therapy.

Step 2: First-Line Intervention

• Hyperacute rejection: Immediate graft nephrectomy is the only option; no medical therapy reverses this process.
• Acute T-cell mediated rejection (TCMR): High-dose intravenous corticosteroids (e.g., methylprednisolone 250-500 mg/day for 3 days) are the mainstay. This protocol is routinely used to manage immune-related acute kidney injury mimicking TCMR, as described in the management of PD-1 inhibitor nephrotoxicity ^[2]C4.
• Acute antibody-mediated rejection (ABMR): Therapeutic plasma exchange (TPE) is first-line, combined with intravenous immunoglobulin (IVIG). A large retrospective study of 493 TPE sessions across 85 patients reported that 21% of procedures were for acute kidney transplant rejection, with albumin as the primary replacement fluid (84%) and frozen plasma used in 16%. Adverse events occurred in 5.88% of patients (hypotension, vasovagal reflex, facial edema); no procedure-related deaths were observed ^[69]C4. TPE is classified as Category I by the American Society for Apheresis (ASFA) for antibody-mediated rejection ^[69]C4.

Step 3: Second-Line and Escalation Therapy

For steroid-resistant TCMR (persistent creatinine elevation after 5-7 days), consider lymphocyte-depleting agents such as anti-thymocyte globulin (dosing per institutional protocol). For ABMR refractory to TPE and IVIG, tocilizumab , an anti-interleukin-6 receptor antibody, has been used successfully. In a case report, a patient with rheumatoid arthritis and end-stage renal disease on hemodialysis received full-dose tocilizumab, achieving sustained remission for four years with no adverse events; the authors noted tocilizumab is used for both RA and kidney transplant rejection ^[68]C4. This suggests tocilizumab is a viable option for resistant ABMR, though clinical trials are needed.

Step 4: Monitoring and Titration

Monitor serum creatinine, urine output, and DSA titers daily during therapy. Donor-derived cell-free DNA (dd-cfDNA) is an emerging biomarker: levels above 2.45% have been associated with ABMR and 1.3% with TCMR, compared with 0.44% in healthy patients; a decline in dd-cfDNA may signal treatment response ^[67]D5. However, dd-cfDNA is not yet standard of care. Ensure CMV surveillance, as seroprevalence of CMV IgG is 88.7% in hemodialysis patients and reactivation can be triggered by immunosuppression, potentially contributing to rejection ^[34]C4.

Step 5: Transition to Long-Term Management

Once the acute rejection episode has resolved (creatinine stabilizes or improves, DSA decline), shift to maintenance immunosuppression and long-term surveillance. This is covered in the next section.

Treatment Algorithm

Figure 1: Acute management algorithm for kidney transplant rejection. Adapted from ^{[2]C4[68]C4[69]C4}.

Drug/Modality Comparison Table

What NOT to Do

• Do not delay hemodialysis for severe hyperkalemia or pulmonary edema while awaiting biopsy results; urgent dialysis per AEIOU criteria is safe.
• Do not use high-dose corticosteroids alone for ABMR; TPE is required to remove circulating DSA.
• Do not continue TPE without monitoring for hypocalcemia (citrate toxicity) and coagulopathy.

Controversies and Guideline Disagreement

No major guideline disagreements were identified in the reviewed evidence. However, the role of dd-cfDNA as a real-time monitoring tool remains under investigation, and its incorporation into acute management algorithms is not yet universal ^[67]D5. The use of tocilizumab for ABMR is based on limited case reports; larger studies are needed to confirm efficacy ^[68]C4.

Pearl: The type of acute rejection dictates the first-line intervention: corticosteroids for TCMR, TPE combined with IVIG for ABMR, and immediate graft nephrectomy for hyperacute rejection ^[2]C4[69]C4.

After addressing acute rejection episodes, the long-term management of kidney transplant recipients focuses on optimizing maintenance immunosuppression, managing chronic antibody-mediated rejection (ABMR), and mitigating factors that lead to graft loss, including medication nonadherence and cardiovascular comorbidities. Strategies must balance rejection prevention with nephrotoxicity, infection risk, and malignancy.

Step 1: Optimizing Maintenance Immunosuppression

Chronic calcineurin inhibitor (CNI) nephrotoxicity contributes to progressive graft dysfunction. The phase 3 trial by Budde et al. (2021) demonstrated that conversion from CNI- to belatacept-based maintenance immunosuppression in stable recipients (6- post-transplant) yields similar 24-month graft survival (98% vs 97%; adjusted difference 0.8, 95% CI -2.1 to 3.7) and higher eGFR (55.5 vs 48.5 mL/min/1.73 m²) ^[26]A1b. Biopsy-proven acute rejection (BPAR) occurred in 8% of belatacept recipients vs 4% with CNI, but de novo donor-specific antibodies (dnDSA) were lower (1% vs 7%). Belatacept (5 mg/kg IV every 4 weeks) is a reasonable option for patients with CNI toxicity or high DSA risk, acknowledging the trade-off of a modest BPAR increase. For patients with concurrent atrial fibrillation , direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists based on a propensity-matched analysis of 1367 recipients: DOACs were associated with lower composite outcome (HR 0.66) and lower kidney transplant rejection (HR 0.46) ^[77]B2b.

Step 2: Managing Late Antibody-Mediated Rejection

Late ABMR is a leading cause of graft failure. Evidence from four RCTs informs current therapy:

• Clazakizumab (anti-IL-6 antibody, 25 mg SC every 4 weeks) in a phase 2 pilot trial (n=20) slowed eGFR decline vs placebo (-0.96 vs -2.43 mL/min/1.73 m²/month; P=0.04) and was associated with decreased DSA and histologic improvement (molecular ABMR score negative in 38.9%, resolution of morphologic activity in 22.2% at 51 weeks) ^[7]A1b. However, serious infections occurred in 25% of treated patients, and two patients (10%) developed diverticular complications leading to trial withdrawal. Clazakizumab may be considered in carefully selected patients with active late ABMR, but its use is not yet standard and requires close monitoring for infection.

• Bortezomib (1.3 mg/m² IV on days 1, 4, 8, 11 for two cycles) was evaluated in the BORTEJECT trial (n=44). The trial failed to show benefit in eGFR slope (difference 0.5 mL/min/1.73 m² per year; P=0.86), 24-month measured GFR, graft survival, DSA levels, or histologic/molecular features, and was associated with gastrointestinal and hematologic toxicity ^[6]A1b. Do not use bortezomib for late ABMR outside of clinical trials.

• Complement inhibition with recombinant C1 inhibitor has shown promise in preclinical models but lacks human trial data ^[73]D5.

• Losartan should be considered in patients with angiotensin II type 1 receptor antibodies (AT1R-Ab) who present with acute rejection, especially if C4d-negative and HLA-DSA-negative. In a pediatric case report, prompt introduction of losartan resulted in excellent clinical and histologic recovery ^[19]C4.

Step 3: Addressing Cost-Related Medication Nonadherence

Cost-related nonadherence is a critical, preventable cause of graft loss. A survey of all U.S. kidney transplant programs (n=254, >99% response rate) found that >70% of programs report patients having an extremely or very serious problem paying for medications; 47% of programs indicate that >40% of their patients have difficulty paying; and 68% of programs report deaths and graft losses attributable to cost-related nonadherence ^[33]C4. Continuous insurance coverage for outpatient immunosuppressive drugs is essential. Clinicians should proactively screen for cost barriers, connect patients with financial assistance programs, and advocate for lifetime Medicare coverage of immunosuppressants.

Step 4: Nephroprotective and Cardiovascular Risk Management

Standard nephroprotective measures, RAAS blockade, SGLT2 inhibitors, blood pressure control, and statin therapy, apply to transplant recipients, though the evidence base is extrapolated from the general CKD population. For patients with atrial fibrillation, DOACs are preferred over VKAs (see Step 1) ^[77]B2b.

Step 5: Surveillance and Monitoring

While surveillance biopsy remains the gold standard for detecting subclinical rejection, novel biomarkers may reduce dependence on invasive procedures. Peripheral blood gene expression profiling (multiple classifiers) can discriminate acute rejection from acute dysfunction with no rejection (AUC 0.84-0.97) ^[56]B3b. Total circulating cell-free nucleosomes (H3) have an acceptable AUC of 0.73 and a negative predictive value of 92.9%, suggesting that a negative test makes acute rejection unlikely ^[32]B2b. Donor-derived cell-free DNA (dd-cfDNA) is a sensitive biomarker for early detection, as illustrated by a case of nivolumab -induced rejection where dd-cfDNA ratio rose to 23% within 12 days of therapy ^[55]C4. These tools are adjunctive but not yet standard of care.

Dosing and Evidence Table

What NOT to Do

• Do not use bortezomib for late ABMR outside of clinical trials; it is ineffective and toxic ^[6]A1b.
• Do not treat isolated v-lesions (intimal arteritis) with intensified immunosuppression without evidence of TCMR or AMR; recent evidence suggests many v-lesions reflect non-immune injury mechanisms, and overtreatment may cause harm ^[78]D5.
• Exercise extreme caution with immunomodulatory agents for cancer (lenalidomide, immune checkpoint inhibitors) in transplant recipients; they can precipitate acute rejection. Lenalidomide triggered acute rejection in a case report ^[72]C4; nivolumab led to graft loss requiring transplant nephrectomy ^[55]C4.

Controversies and Guideline Disagreement

Pearl: Conversion from CNI to belatacept-based immunosuppression in stable recipients improves renal function and reduces de novo DSA, but the modest increase in BPAR (8% vs 4%) requires careful patient selection ^[26]A1b; cost-related nonadherence remains a major preventable cause of graft loss and must be addressed systematically ^[33]C4.

After addressing fluid and electrolyte disorders, the clinician must select the optimal kidney replacement strategy for patients with progressive allograft dysfunction or those awaiting transplantation. While dialysis sustains life, kidney transplantation remains the definitive therapy, offering superior survival and quality of life, but it carries the inherent risk of allograft rejection.

Modality Selection and Bridging

For patients with end-stage renal disease, preemptive kidney transplantation is the preferred approach, avoiding the morbidity and mortality associated with prolonged dialysis. When transplantation is not immediately available, dialysis serves as a bridge. The choice between hemodialysis and peritoneal dialysis should be individualized, considering vascular access options, peritoneal membrane integrity, and the patient's ability to maintain adherence. No direct comparative evidence from the provided references addresses this selection, but the ultimate goal remains timely transplantation.

Immunologic Evaluation for Transplant Candidates

Comprehensive immunologic assessment is essential before listing. This includes HLA typing , screening for donor-specific antibodies (DSA), and crossmatching. A positive flow cytometric T-cell crossmatch (FCXM-T) does not preclude transplantation; with appropriate desensitization, including antithymocyte globulin and intravenous immunoglobulin, one-year outcomes can be comparable to those of low-risk recipients ^[75]B2b. Non-HLA antibodies are increasingly recognized as contributors to rejection, particularly in DSA-negative cases. Preformed anti-vimentin antibodies have been associated with early antibody-mediated rejection (AMVR) in the setting of ischemia-reperfusion injury ^[80]C4. De novo anti-endothelial cell antibodies (AECAs) independently increased the risk of rejection (OR 5.17; P<0.001) in a 10-year cohort ^[82]B2b. Anti-MICA antibodies, present in 11.4% of pretransplant sera, were associated with lower 1-year graft survival (88.3% vs 93.0%; P=0.01), even in well-HLA-matched recipients ^[84]B2b. These findings support the inclusion of non-HLA antibody testing in high-risk or unexplained rejection cases.

Maintenance Immunosuppression and Rejection Prevention

After transplantation, effective immunosuppression is the cornerstone of graft survival. Calcineurin inhibitors (CNIs) remain standard, but their nephrotoxicity has prompted alternative strategies. In a randomized phase 3b trial, conversion from CNI to belatacept in stable recipients (6-60 months post-transplant) resulted in higher eGFR at 24 months (55.5 vs 48.5 mL/min/1.73 m²; adjusted difference 0.8, 95.1% CI -2.1 to 3.7) and lower de novo DSA (1% vs 7%), although biopsy-proven acute rejection was numerically higher (8% vs 4%) ^[26]A1b. This trade-off may be acceptable for patients with declining renal function or emerging DSA. Cost-related nonadherence to immunosuppression remains a major threat; over 70% of U.S. transplant programs report that patients have serious difficulty paying for medications, and 68% have observed graft loss or death attributable to nonadherence ^[33]C4.

Noninvasive Monitoring for Rejection

Advances in biomarkers reduce reliance on invasive biopsies. Urinary CXCL9 and CXCL10, integrated with clinical markers (eGFR, DSA, polyoma viremia), achieved an AUC of 81.3% (95% CI 77.6-85.0) for detecting acute rejection, potentially avoiding 59 protocol biopsies per 100 patients ^[42]B2b. The Tutivia peripheral blood gene signature predicted early acute rejection with an AUC of 0.69, superior to serum creatinine alone (AUC 0.51) ^[52]B2b. A meta-analysis of dd-cfDNA demonstrated pooled sensitivity of 81% and specificity of 80% for antibody-mediated rejection (ABMR), with an AUC of 0.87 (95% CI 0.84-0.90) ^[53]A1a. Combining dd-cfDNA >0.5% and urine CXCL10 may differentiate TCMR (tubulitis) from AMR (microvascular injury): dd-cfDNA was independently associated with AMR (OR 21.9) and TCMR (OR 5.37), while CXCL10 predicted TCMR in models without dd-cfDNA ^[62]B3b.

Treatment of Established Rejection and Comorbidities

For late ABMR, the BORTEJECT trial found that bortezomib did not prevent GFR decline (eGFR slope difference 0.5 mL/min/1.73 m² per year; P=0.86) and was associated with gastrointestinal and hematologic toxicity ^[6]A1b. In contrast, a pilot trial of the anti-IL-6 antibody clazakizumab showed a slower eGFR decline during the 12-week placebo-controlled phase (-0.96 vs -2.43 mL/min/1.73 m² per month; P=0.04), with modulation of DSA and histologic activity ^[7]A1b. Clinicians should also manage comorbidities that affect rejection risk. In kidney transplant recipients with atrial fibrillation , direct oral anticoagulants were associated with a lower risk of the composite outcome (HR 0.66, 95% CI 0.50-0.87) and a reduced risk of rejection (HR 0.46, 95% CI 0.30-0.71) compared to vitamin K antagonists ^[77]B2b. BK virus nephropathy can be treated with third-party BK virus-specific cytotoxic T lymphocytes, which reduced viremia without provoking rejection ^[90]C4.

Pearl: Preemptive kidney transplantation is the optimal RRT modality; for patients bridged with dialysis, early immunologic evaluation and desensitization can improve access to transplantation, and modern immunosuppression (e.g., belatacept) may reduce DSA and improve graft function, but careful monitoring for rejection is required ^[26]A1b.

Since kidney transplantation became the preferred renal replacement therapy, the central challenge has been balancing immunosuppression to prevent rejection against drug toxicity. The evolution of treatment reflects a succession of paradigms: from broad lymphodepletion to targeted T-cell modulation, and from managing acute cellular rejection to addressing antibody-mediated injury.

The Early Era: Steroids, Azathioprine, and Anti-Lymphocyte Globulin

In the 1960s-1970s, high-dose corticosteroids and azathioprine formed the backbone of immunosuppression. Prophylactic anti-lymphocyte globulin (ALG) was introduced but lacked standardization. The first monoclonal antibody, muromonab-CD3 (OKT3), was used for prophylaxis in a 1986 trial: 6 patients receiving OKT3 alone had a dramatic T-cell depletion, but all experienced rejection a mean of 12.8 ± 2.9 days after surgery, coinciding with anti-OKT3 antibodies ^[94]A1b. OKT3 induced cytokine release syndrome (fever, chills, diarrhea) and was abandoned for prophylaxis due to immunogenicity and toxicity ^[94]A1b. A human-mouse chimeric CD7 antibody (SDZCHH380) delayed rejection to day 35 but was not further developed ^[93]A1b.

The Calcineurin Inhibitor Era

Cyclosporine (approved 1983) revolutionized transplantation, reducing acute rejection rates dramatically. Tacrolimus later emerged as a more potent CNI, becoming the cornerstone of modern regimens. However, nephrotoxicity and chronic allograft dysfunction drove interest in alternatives. The phase 3 BELAT study (NCT01820572) assessed conversion from CNI to belatacept, a selective T-cell costimulation blocker, in stable recipients 6-60 months post-transplant. At 24 months, rates of death or graft loss were similar (98% vs 97%), but belatacept yielded higher eGFR (55.5 vs 48.5 mL/min/1.73 m²) and lower de novo donor-specific antibody (dnDSA) incidence (1% vs 7%), albeit with a numerically higher biopsy-proven acute rejection (BPAR) rate (8% vs 4%) ^[26]A1b. Belatacept thus offers a nephrosparing alternative, though conversion requires careful patient selection.

Induction Therapy and Acute Rejection Treatment

Induction with rabbit anti-thymocyte globulin (Thymoglobulin) or basiliximab became standard. The US Multicenter Phase III trial compared Thymoglobulin to Atgam (equine ATG) for treatment of acute rejection, using Banff criteria for enrollment and serum creatinine as a response marker ^[95]D5. Thymoglobulin has since become the preferred agent for severe cellular rejection. TOL101, a murine IgM targeting the αβ TCR, showed promise in a phase 2 trial (5-10 daily doses; 21-28-42-42-42 mg regimen), with 13.9% BPAR and no dnDSA, but development was halted after a self-limiting urticarial rash in three patients ^[27]C4.

Antibody-Mediated Rejection: Failed and Emerging Therapies

Late antibody-mediated rejection (ABMR) remains a leading cause of graft loss. The BORTEJECT trial (NCT01820572) randomized 44 patients with DSA-positive ABMR to bortezomib (1.3 mg/m² IV on days 1, 4, 8, 11 per cycle) or placebo. The eGFR slope difference was insignificant (0.5 mL/min/1.73 m²/year; 95% CI -4.8 to 5.8; P=0.86), and bortezomib caused gastrointestinal and hematologic toxicity ^[6]A1b. This negative trial concluded that bortezomib does not prevent GFR loss or reduce DSA in late ABMR. The phase 2 pilot trial of clazakizumab (25 mg subcutaneously every 4 weeks) in late ABMR showed a slower eGFR decline versus placebo (-0.96 vs -2.43 mL/min/1.73 m²/month; P=0.04) and histologic improvement in some patients, but serious infectious events occurred in 25% of treated patients ^[7]A1b. A sub-study found no clinically meaningful effect on CYP3A4/CYP2C19 metabolism, suggesting no drug interaction with calcineurin inhibitors ^[74]A1b. Clazakizumab is under investigation but requires careful monitoring.

Noninvasive Monitoring and Molecular Diagnostics

Parallel to pharmacologic advances, efforts to reduce biopsy reliance have produced gene expression signatures in peripheral blood. In 2004, microarrays distinguished acute rejection from stable function and acute dysfunction without rejection in biopsies and PBLs ^[96]B3b. Later work validated a 200-probeset classifier with sensitivity 82-100% and specificity 76-95% for acute rejection ^[56]B3b. Targeted proteomics in belatacept-treated patients identified CD5, CD8A, NCR1, TNFRSF4, and TNFRSF9 as predictive of TCMR (AUC 0.83-0.91) ^[60]B3b. Urinary chemokine CXCL9/CXCL10 integrated with clinical markers achieved AUC 81.3% for detection of acute rejection and could avoid 59 protocol biopsies per 100 patients ^[42]B2b. Circulating cell-free nucleosomes (H3) also showed a high negative predictive value (92.9%) for rejection ^[32]B2b. These tools are not yet standard but represent the next frontier.

Abandoned and Unsuccessful Approaches

Beyond bortezomib, several strategies failed: anti-CD7 mAb did not prevent rejection ^[93]A1b; OKT3 prophylaxis was abandoned due to immunogenicity ^[94]A1b; TOL101 was not developed further ^[27]C4; and high-dose steroid-only protocols were replaced by multimodality regimens. The observation that perforin and granzyme A/B are not required for T-cell-mediated rejection lesions ^[97]D5 redirected focus away from targeting cytotoxic granules. Gene therapy with IL-10 prolonged allograft survival in rats but has not translated to human trials ^[17]D5.

Controversies and Guideline Disagreement

Pearl: The failure of bortezomib in the BORTEJECT trial underscores that promising open-label results do not replace randomized evidence, this lesson has refocused late ABMR treatment toward IL-6 blockade and careful patient selection.

The progressive loss of graft function from chronic rejection creates a systemic syndrome indistinguishable from native CKD, anemia, mineral bone disease, cardiovascular disease, and uremic toxicity, but with the added layer of chronic immunosuppression that amplifies infection and malignancy risk. Management follows standard CKD guidelines, but every therapeutic decision must be weighed against the risk of allograft injury and drug interactions with immunosuppressants.

Anemia of CKD and Iron Deficiency

Chronic rejection impairs erythropoietin production, typically requiring erythropoiesis-stimulating agents (ESAs) when hemoglobin falls below 10 g/dL. Iron deficiency, from ongoing blood loss, uremic platelet dysfunction, or gastrointestinal bleeding, must be corrected before or concurrent with ESA therapy. Target hemoglobin is 10-11.5 g/dL, avoiding levels above 13 g/dL due to cardiovascular risk. The presence of chronic inflammation from rejection can blunt ESA response, often necessitating higher doses or switching to a longer-acting agent.

CKD-Mineral and Bone Disorder (CKD-MBD)

With declining GFR, phosphate retention, vitamin D deficiency, and secondary hyperparathyroidism develop predictably. Phosphate binders (e.g., calcium acetate, sevelamer) should be initiated when serum phosphate exceeds the normal range. Calcitriol or vitamin D analogs are used to suppress PTH, targeting levels based on KDIGO guidelines. The added risk of post-transplant diabetes and corticosteroid use exacerbates bone loss, so dual-energy X-ray absorptiometry (DXA) screening is recommended at 1 year post-transplant and repeated if immunosuppression includes high-dose steroids.

Cardiovascular Disease

Cardiovascular events are the leading cause of death with functioning graft. Chronic rejection accelerates cardiovascular risk through hypertension , dyslipidemia, and left ventricular hypertrophy . Blood pressure target is <130/80 mmHg; amlodipine or diltiazem are preferred calcium-channel blockers because they do not affect calcineurin inhibitor levels. Statins (e.g., atorvastatin 10-20 mg daily) are indicated for all transplant recipients regardless of baseline LDL-C, as the 4D trial established benefit in this population. Aspirin 75-100 mg daily is used for primary prevention in patients with additional risk factors, though bleeding risk from uremic platelet dysfunction must be considered.

Infectious Complications and Viral Reactivation

Chronic immunosuppression, particularly with tacrolimus and antithymocyte globulin , predisposes to viral reactivation. In a cross-sectional study of 98 patients with suspected rejection, active viremia was detected for human cytomegalovirus (HCMV) in 18.36%, Epstein-Barr virus (EBV) in 7.14%, and BK polyomavirus (BKV) in 5.10% ^[98]C4. The odds of HCMV viremia were 2.84 times higher with tacrolimus and 3.01 times higher with antithymocyte globulin exposure ^[98]C4. In pediatric recipients, BKPyV-DNAemia was associated with a more than twofold increased risk of late TCMR (HR 2.22), de novo donor-specific antibodies/ABMR (HR 2.64), and graft function deterioration (HR 2.73) ^[99]B2b. Thus, regular viral surveillance (PCR for CMV, EBV, BKV) is mandatory, and preemptive reduction of immunosuppression is the cornerstone of management, albeit with the trade-off of increased alloimmune risk.

Malignancy and Immunomodulatory Therapies

Chronic rejection patients are at elevated risk for post-transplant lymphoproliferative disorder (PTLD) and non- melanoma skin cancer. The use of immunomodulatory agents for cancer, such as lenalidomide for multiple myeloma or nivolumab for melanoma, can precipitate acute rejection. A case report documented acute ABMR within 12 days of nivolumab initiation, with dd-cfDNA rising to 23%, leading to graft nephrectomy ^[55]C4. Similarly, lenalidomide therapy has been associated with acute rejection in a kidney transplant recipient with multiple myeloma ^[72]C4. These cases underscore the need for close collaboration between transplant nephrology and oncology, with consideration of dd-cfDNA monitoring during ICI therapy.

Other Systemic Associations

Psoriasis, a chronic immune-mediated skin disorder, has been linked to increased risk of renal allograft failure. In a USRDS analysis of 151,272 transplant recipients, those with a pre-existing psoriasis diagnosis had significantly reduced graft survival on Kaplan-Meier estimation, with a hazard ratio that remained significant after adjustment for demographics and clinical risk factors ^[12]B2b. The systemic inflammation underlying psoriasis may contribute to accelerated chronic rejection. Pseudorejection phenomena, isolated v-lesions or microvascular inflammation without anti-HLA antibodies, can mimic rejection and lead to unnecessary immunosuppression intensification ^[78]D5. Non-HLA antibodies, including anti-vimentin and anti-AT1R, are associated with early acute microvascular rejection and may contribute to chronic graft injury ^[11]B3b, ^[80]C4. Complement activation, particularly through the alternative pathway, amplifies T-cell-mediated rejection and may promote fibrosis ^[85]D5.

Pearl: In any kidney transplant recipient with chronic graft dysfunction, a rising creatinine should trigger not only a biopsy for rejection but also simultaneous viral PCRs (CMV, EBV, BKV), a treatable viral infection can mimic rejection, and immunosuppression reduction rather than augmentation may be the correct response.

These chronic systemic sequelae reflect the cumulative burden of alloimmune injury, and the natural history of kidney transplant rejection is ultimately defined by the trajectory of graft function loss and the risk of graft failure. Despite a one-third reduction in crude acute rejection rates between 1997 and 2004, graft survival has remained constant, indicating that the character of rejection, not solely its frequency, determines long-term outcomes ^[40]B2b.

Graft Survival after Rejection

Acute rejection within the first 6 months confers a sustained increase in the risk of graft loss after 6 months (adjusted HR 1.69). Late rejection (first episode ≥90 days post-transplant) carries an even higher risk (HR 2.46), as does vascular rejection (HR 2.07) ^[40]B2b. The presence of de novo donor-specific antibodies (dnDSA) is a powerful predictor: among 121 recipients, graft survival was 87.1% in dnDSA-positive patients versus 97.8% in dnDSA-negative patients at follow-up (p = 0.007) ^[38]B3b. In antibody-mediated rejection (ABMR), subphenotypes defined by biopsy lesions have distinct natural histories. The pgABMR subphenotype (peritubular capillaritis/glomerulitis) presents early (median <2 years), is frequently mixed with T-cell-mediated rejection, and is associated with nonadherence; the cgABMR subphenotype (glomerular double contours) presents late (median 9 years); and the combined pgcgABMR subphenotype dominates at all time intervals ^[15]B2b. Notably, DSA is not detected in 29% of pgcgABMR and 46% of cgABMR cases, yet graft failure rates are similar to DSA-positive cases ^[15]B2b. When biopsies are reclassified by molecular transcriptomics, 14% of indication biopsies are undetermined for AMR by standard histology; of these, 56% have a molecular signature of AMR and suffer a 5-year death-censored graft loss rate of 63% (15 of 24), equivalent to that of biopsy-proven AMR ^[101]D5.

Predictors of Progression

Biomarkers and Emerging Prognostic Tools

Peripheral blood whole-genome gene expression classifiers distinguish acute rejection from stable function and acute dysfunction without rejection with AUC values ranging from 0.817 to 0.968 in validation cohorts ^[56]B3b. The number of donor-specific IL-21-producing cells, measured by ELISPOT before and after transplantation, predicts both early and late rejection, with low frequencies associated with higher rejection-free survival ^[102]B2b. S100A8 and S100A9 expression in rejection biopsies, reflecting myeloid-derived suppressor cell activity, is linked to improved graft outcome ^[8]B2b. Single-cell RNA sequencing of rejection biopsies reveals that kidney structural cells, endothelial cells of glomeruli and peritubular capillaries, and proximal tubular epithelial cells, actively participate in alloimmune signaling and undergo a profound metabolic shutdown, which is associated with poor kidney function ^[88]C4. The complement system, activated through classical and lectin pathways by anti-HLA antibodies, amplifies graft injury; emerging data indicate that locally produced complement components within the graft also promote T-cell-mediated rejection ^[85]D5.

Natural History by Rejection Phenotype

T-cell-mediated rejection (TCMR) is often reversible with appropriate therapy, but late-onset or vascular TCMR carries a substantially higher risk of graft loss ^[40]B2b. ABMR is typically progressive: the pgABMR subphenotype may transition to transplant glomerulopathy (cg) over time, and the cgABMR subphenotype, once established, portends a poor prognosis ^[15]B2b. In a randomized trial of the anti-IL-6 antibody clazakizumab in late ABMR, the mean eGFR decline was slower in the treatment group (-0.96 vs. -2.43 mL/min/1.73 m² per month, p = 0.04), and after 51 weeks, 38.9% of patients had a negative molecular ABMR score, 27.8% had disappearance of C4d deposits, and 22.2% had resolution of morphologic ABMR activity ^[7]A1b. In contrast, a randomized trial of bortezomib in late ABMR showed no benefit on eGFR slope, graft survival (81% vs. 96%), DSA levels, or histology, despite significant toxicity ^[6]A1b. Conversion from calcineurin inhibitor- to belatacept-based maintenance immunosuppression in stable recipients improved eGFR (55.5 vs. 48.5 mL/min/1.73 m² at 24 months) and reduced the incidence of de novo DSA (1% vs. 7%), though it was associated with a numerically higher rate of biopsy-proven acute rejection (8% vs. 4%) ^[26]A1b.

Novel Therapies and Prognostic Impact

In nonhuman primate models, inhibition of CD40/CD154 costimulatory signaling dramatically prolongs rejection-free survival: median survival 352 days with anti-CD154 and 131 days with anti-CD40, compared with 6 days in untreated controls ^[100]D5. Adeno-associated viral vector-mediated gene delivery of IL-10 in a rat model improved allograft survival from 22% to 90% ^[17]D5. These approaches, while not yet in clinical use, highlight the potential to alter the natural history of rejection at its earliest stages. The familial aggregation of rejection-free survival (GIF 2.45 vs. 2.08, p = 0.04) suggests a heritable component that may inform future risk stratification ^[36]B3b.

Pearl: The single strongest predictor of graft loss after rejection is the presence of de novo donor-specific antibodies, particularly when accompanied by microcirculation inflammation on biopsy; graft survival at 5 years is approximately 63% in molecularly reclassified DSA-negative ABMR, underscoring the need for sensitive detection methods ^{[14]C4[101]D5}.

Prognosis varies not only by rejection phenotype but also by patient age, immune status, and comorbidities, necessitating population-specific modifications in diagnostic thresholds and therapeutic strategies.

Pediatrics

Pediatric kidney transplant recipients face unique challenges: age-dependent pharmacokinetics, growth, and adherence. Cost-related immunosuppressive medication nonadherence is a significant issue, though reportedly more problematic for adult than pediatric patients ^[33]C4. Familial clustering of rejection has been studied, with a trend toward increased familiality in recipients with grade ≥1A rejection but not reaching statistical significance ^[36]B3b. No pediatric-specific treatment trials are represented in the available evidence, so dosing and monitoring must be extrapolated from adult data with careful attention to weight-based adjustments.

Pregnancy

Pregnancy after kidney transplantation requires careful immunosuppression management , although the provided references do not contain pregnancy-specific outcome data. Standard contraindications apply: mycophenolate mofetil and mTOR inhibitors are teratogenic and should be avoided or switched to calcineurin inhibitors and corticosteroids before conception. The use of bortezomib ^[6]A1b and clazakizumab ^[7]A1b is contraindicated in pregnancy due to teratogenicity risk, but these agents are rarely used in this setting. Belatacept conversion ^[26]A1b may be considered pre-conception, but its safety in pregnancy is not established.

Elderly

Older recipients are at increased risk for drug interactions, toxicity, and rejection triggered by concurrent therapies. The case of a 65-year-old woman with multiple myeloma who developed acute rejection after lenalidomide treatment illustrates the risk of immunomodulatory cancer therapies precipitating rejection ^[72]C4. Desensitization with antithymocyte globulin, rituximab , and IVIG enabled successful transplantation in FCXM-T-positive patients, with outcomes comparable to low-risk patients at 12 months after overlap weighting, suggesting that aggressive perioperative management can mitigate risk in older sensitized patients ^[75]B2b. AL amyloidosis patients can undergo transplantation successfully after achieving complete hematologic response, with no difference in survival between treatment groups, though cellular rejection occurred in 5 of 19 patients ^[37]C4.

Immunocompromised Patients (including diabetes, autoimmune disease, infection)

Patients with pre-existing autoimmune conditions or infections require tailored approaches. Psoriasis is associated with a significantly increased hazard ratio for renal allograft failure, likely due to systemic inflammation ^[12]B2b. BK virus nephropathy can be treated with third-party BK virus-specific cytotoxic T lymphocytes (CTLs), which demonstrated antiviral activity without causing rejection or graft loss in a small study ^[90]C4. The use of immunomodulatory agents like lenalidomide for multiple myeloma can precipitate acute rejection, necessitating close collaboration between oncologists and transplant nephrologists ^[72]C4. For patients with light chain amyloidosis, kidney transplantation can be performed with outcomes similar to other recipients, provided hematologic remission is achieved ^[37]C4.

Pearl: In elderly or immunocompromised patients, the use of immunomodulatory cancer therapies (e.g., lenalidomide) can precipitate acute rejection; close monitoring and collaboration with oncology are essential ^[72]C4.

The preceding discussion of pregnancy in transplant recipients underscores the need for vigilant monitoring across all patient subgroups; the same principle extends to the lifelong surveillance for rejection that defines post-transplant care. While primary prevention of rejection begins with modifiable risk factors, the cornerstone of modern management is structured screening using validated noninvasive biomarkers.

Primary Prevention

Avoidance of nephrotoxic insults, nonsteroidal anti-inflammatory drugs, iodinated contrast with inadequate prophylaxis, and uncontrolled hypertension or hyperglycemia, remains the foundation of graft preservation. For contrast-induced acute kidney injury, isotonic crystalloid hydration (1 mL/kg/h for 12 h pre- and post-procedure) is standard, though no specific trial in transplant recipients is cited here. Blood pressure targets (<130/80 mm Hg) and glycemic control (HbA1c <7%) are extrapolated from general chronic kidney disease guidelines. These measures do not replace immunosuppression but mitigate nonimmunologic injury that can trigger or amplify alloimmune responses.

Screening for Rejection: Noninvasive Biomarkers

Tissue biopsy remains the gold standard for rejection diagnosis, but its invasiveness and sampling error limit routine use ^[46]D5. A growing armamentarium of blood- and urine-based tests now enables earlier detection and may reduce the need for surveillance biopsies.

Blood-based biomarkers

• Donor-derived cell-free DNA (dd-cfDNA): Levels rise sharply during rejection. In a case of nivolumab -triggered rejection, dd-cfDNA ratio increased to 23% within 12 days of the first dose ^[55]C4. In a real-life appraisal of 230 consecutive biopsies, high dd-cfDNA (Viracor-TRAC) combined with donor-specific antibodies (DSA) in for-cause biopsies predicted antibody-mediated rejection (AMR) or microvascular inflammation with an AUROC of 0.817 (P < 0.001), outperforming creatinine and DSA alone (AUROC <0.65) ^[108]B2b.
• Torque teno virus (TTV): Emerging as an indirect indicator of net immunosuppression; higher TTV loads correlate with lower rejection risk but higher infection risk ^[106]D5.

Urine-based biomarkers

• Urinary CD8+HLA-DR+ T cells: Flow cytometry of 380 urine samples showed these cells were most distinctive for T cell-mediated rejection (TCMR), with an AUC of 0.91, specificity 95.9%, and sensitivity 76.5% ^[107]B2b.
• Neutrophil gelatinase-associated lipocalin (NGAL): Very high plasma levels were observed before acute rejection, with predictive value when measured within 72 hours of the event ^[103]A1a.

Surveillance Protocols

Current practice integrates protocol biopsies (often at 3, 6, and 12 months post-transplant) with for-cause biopsies triggered by rising creatinine or proteinuria. In the Tutivia validation cohort, 71% of biopsies were surveillance/protocol procedures ^[52]B2b. Noninvasive biomarkers are poised to reduce this burden: a negative Tutivia result (score <50) provides a NPV of 0.79, potentially allowing deferral of biopsy in low-risk patients ^[52]B2b. Similarly, a low urinary metabolite score combined with stable eGFR may extend the interval between surveillance biopsies ^[109]B2b. For high-risk patients, those with preformed DSA, prior rejection, or BK polyomavirus nephropathy, more frequent monitoring (e.g., every 3 months for the first year) is warranted, though specific intervals are not standardized in the cited literature.

Patient Education

Patients rank rejection and graft failure as their most feared outcomes ^[46]D5. Education should emphasize strict adherence to immunosuppression, recognition of subtle symptoms (fever, oliguria, graft tenderness), and the importance of attending scheduled monitoring visits. The availability of noninvasive tests may improve compliance by reducing the perceived burden of surveillance biopsies.

Controversies and Guideline Disagreement

Pearl: In for-cause biopsies, combining dd-cfDNA with DSA improves diagnostic accuracy for antibody-mediated rejection (AUROC 0.817) and should be considered when biopsy is equivocal or deferred ^[108]B2b.